ProCE Banner Activity

Interactive Tool for Managing BTK Inhibitor−Associated AEs in Hematologic Malignancies: A Global Perspective

Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with BTK inhibitors from 5 international experts in managing patients with hematologic malignancies.

Released: August 15, 2023

Share

Faculty

Florence Cymbalista

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Toby A Eyre

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Arnon Kater

Arnon Kater, MD, PhD

Professor of Hematology
Deputy Head of Department
Chairman, HOVON CLL Working Group and President, HOVON Executive Board
Department of Hematology
Lymphoma and Myeloma Research Amsterdam
Amsterdam, Netherlands

Stephan Stilgenbauer

Stephan Stilgenbauer, MD

Medical Director, Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL
Department of Internal Medicine III
Comprehensive Cancer Center Ulm
University Medical Center Ulm
Ulm, Germany

Alessandra Tedeschi

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Florence Cymbalista, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Janssen, Lilly.

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Toby Eyre, MBCHB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, Beigene, Incyte, Janssen, Kite/Gilead, Lilly, Roche, Secura Bio; researcher: AstraZeneca, Beigene.

Arnon Kater, MD, PhD

Professor of Hematology
Deputy Head of Department
Chairman, HOVON CLL Working Group and President, HOVON Executive Board
Department of Hematology
Lymphoma and Myeloma Research Amsterdam
Amsterdam, Netherlands

Arnon Kater, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol-Myers Squibb, Janssen, Lava, LINK Immunotherapeutics, Roche/Genentech.

Stephan Stilgenbauer, MD

Medical Director, Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL
Department of Internal Medicine III
Comprehensive Cancer Center Ulm
University Medical Center Ulm
Ulm, Germany

Stephan Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem; research support: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem. 

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Alessandra Tedeschi, MD: Consultant/Advisor/Speaker: AbbVie, AstraZeneca, Beigene, Janssen.